Le Lézard
Classified in: Health
Subjects: PDT, BFA

Forum Health Launches Groundbreaking AI Technology to Detect Signs of Heart Disease at an Earlier Stage


Wisconsin clinic is the first in the Forum Health network to use the Multifunction Cardiogramtm? scan, a cutting-edge, non-invasive diagnostic tool transforming cardiovascular care

FLINT, Mich., Sept. 12, 2023 /PRNewswire/ -- Forum Health Fond du Lac, a Forum Health national integrative and functional medicine network, has launched the Multifunction Cardiogramtm (MCGtm) scan for early detection of heart disease and cardiac abnormalities.

Unlike traditional methods that rely on symptom onset, the MCGtm scan uses AI to identify a range of cardiac concerns.

Learn more about the MCGtm scan.

Phil Hagerman, Forum Health CEO: "Our vision is to use advanced technologies like AI in everything we do. The MCGtm scan uses AI to identify potential heart issues before they escalate into life-threatening conditions. Fond du Lac is the first clinic in our network to launch this technology with great success and we plan to expand it to other clinics."

The MCGtm scan is a preventative measure that can be used in youth and general populations that are increasingly at risk of heart-related disease. Unlike traditional methods that rely on the onset of symptoms, the MCGtm scan uses advanced artificial intelligence (AI) technology to identify a wide range of cardiac concerns, including:

Dr. Steven Meress, Forum Health Fond du Lac: "The MCGtm scan is a revolutionary cardiac device. In March 2023, we performed the first round of scans; five months later, 12 out of 12 follow-up scans show improvement. This evidence shows how effective early interventions can be when based off the MCGtm scan and the positive impact on cardiac health."

The Multifunction Cardiogramtm scan is powered by AI-driven technology, which continuously learns and improves with each test conducted. Each scan is compared to a robust database of more than 200,000 patients with established cardiovascular disease and assigned an objective heart dysfunctional burden score. This score ranks the patient's heart health, empowering physicians to make informed decisions and develop personalized treatment plans.

Learn more about Forum Health.

About Forum Health, LLC

Forum Health, LLC is a nationwide provider of personalized healthcare steeped in the powerful principles of functional and integrative medicine. Our providers take a root-cause approach to care exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. For more, visit www.forumhealth.com.

SOURCE Forum Health, LLC


These press releases may also interest you

at 15:30
The professional membership group of the American Hospital Association focused on healthcare marketing has enlisted experts from the advertising agency universe and the provider data sector to share insights about the best methods for reaching and...

at 15:20
Team famous for HIV breakthroughs demonstrates both persistent COVID virus and widespread immune activation in long COVID; provides clear targets for treatment Key points: SARS-CoV-2 double-stranded RNA indicative of viral replication was found in...

at 15:05
CloudMD Software & Services Inc. (the "Company" or "CloudMD"), an innovative health services company transforming the delivery of care, is pleased to announce that it has received a final order from the Supreme Court of British Columbia approving...

at 14:57
Workers at Watsonville Community Hospital represented by Teamsters Local 853 have voted unanimously to ratify a collective bargaining agreement. The new three-year contract includes significant wage increases, a strong benefits package with Teamsters...

at 14:55
The global anti-inflammatory therapeutics market size is estimated to grow by USD 38.7 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 6.3% during the forecast period. Increase in off-label use is...

at 14:45
Pulse Biosciences, Inc. (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, announced today the closing of its rights offering and the final results...



News published on and distributed by: